MyFinsight
Home
Blog
About
MBX Biosciences, Inc. (MBX)
MBX Biosciences, Inc. (MBX)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$8,909K
Free Cash flow
-$23,523K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Accrued expenses
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Accounts payable
Operating lease right-of-use ass...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-37,095
-23,517
-22,062
-21,618
Stock-based compensation expense
6,064
5,484
2,656
2,245
Non cash operating lease expense
120
34
32
32
Accretion and amortization of marketable securities, net
421
579
555
734
Depreciation expense
79
64
60
88
Prepaid expenses and other current assets
-258
725
2,005
1,545
Accounts payable
-3,227
3,972
-861
-2,042
Accrued expenses
11,197
-4,857
4,453
2,038
Other assets
-43
43
-8
-
Operating lease right-of-use assets
2,426
-
0
-65
Operating lease liabilities
2,786
-41
-27
-27
Net cash used in operating activities
-22,622
-20,208
-18,301
-21,536
Purchases of property and equipment
901
437
793
399
Purchases of marketable securities
53,889
154,160
205,430
46,395
Maturities of marketable securities
84,000
57,500
76,250
61,350
Call redemptions of marketable securities
0
0
0
2,500
Net cash (used in) provided by investing activities
29,210
-97,097
-129,973
17,056
Proceeds from public offering, net of underwriting discounts and commissions
-
-
0
187,948
Proceeds from initial public offering, net of underwriting discounts and commissions
-
-
0
0
Proceeds from at-the-market offering, net of underwriting discounts and commissions
0
85,371
-
-
Proceeds from exercise of common stock options
2,194
2,442
955
130
Proceeds from espp purchases
254
-
-
-
Payments related to offering costs
127
378
517
254
Proceeds from the issuance of series c convertible preferred stock
-
-
0
0
Preferred stock issuance costs
-
-
0
0
Net cash provided by financing activities
2,321
87,435
438
187,824
Net decrease in cash and cash equivalents
8,909
-29,870
-147,836
183,344
Cash, cash equivalents and restricted cash, beginning of period
45,419
75,289
223,125
49,351
Cash, cash equivalents and restricted cash, end of period
54,328
45,419
75,289
223,125
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$84,000K
(-35.52%↓ Y/Y)
Proceeds from exercise of
common stock options
$2,194K
(64.96%↑ Y/Y)
Proceeds from espp
purchases
$254K
Net cash (used in)
provided by investing...
$29,210K
(-0.01%↓ Y/Y)
Net cash provided by
financing activities
$2,321K
(74.51%↑ Y/Y)
Canceled cashflow
$54,790K
Canceled cashflow
$127K
Net decrease in cash
and cash...
$8,909K
(193.09%↑ Y/Y)
Canceled cashflow
$22,622K
Purchases of marketable
securities
$53,889K
(-49.32%↓ Y/Y)
Purchases of property and
equipment
$901K
(22.25%↑ Y/Y)
Accrued expenses
$11,197K
(3571.15%↑ Y/Y)
Stock-based compensation
expense
$6,064K
(60.59%↑ Y/Y)
Operating lease
liabilities
$2,786K
(481.63%↑ Y/Y)
Prepaid expenses and
other current assets
-$258K
(69.75%↑ Y/Y)
Non cash operating
lease expense
$120K
(73.91%↑ Y/Y)
Depreciation expense
$79K
(-21.00%↓ Y/Y)
Other assets
-$43K
Payments related to
offering costs
$127K
Net cash used in
operating activities
-$22,622K
(43.60%↑ Y/Y)
Canceled cashflow
$20,547K
Net loss
-$37,095K
(14.31%↑ Y/Y)
Accounts payable
-$3,227K
(-821.92%↓ Y/Y)
Operating lease
right-of-use assets
$2,426K
(328.62%↑ Y/Y)
Accretion and
amortization of marketable...
$421K
(-81.87%↓ Y/Y)
Buy us a coffee